1. ALLA AKTIER
  2. NYHETER
  3. ACOUSORT

AcouSort

Nyheter AcouSort Nyheter alla bolag

Leading global pharma company evaluates AcouWash for quality control in an R&D setting

AcouSort has received an order for a six-month rental and application support for an AcouWash system from a leading global pharma company. Initial revenues amount to EUR 14,000.

The rental period commenced at the beginning of October and was kicked off with an on-site installation and training at one of the customer’s R&D labs. The rental period will continue for a minimum of six months. The aim of the project is to evaluate if AcouSort’s technology can be implemented to improve sample preparation in the customer’s R&D quality control procedures.

“This collaboration is immensely exciting, and we are very much looking forward to working together with this new and important partner to explore AcouWash’s potential for improving quality control in cell culturing workflows. The collaboration is yet another example of how instrument rentals provide a swift route to new and promising collaborations,” says Agnes Michanek, Commercial Director at AcouSort.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Carnegie Investment Bank AB (publ).

Attachments
Leading global pharma company evaluates AcouWash for quality control in an R&D setting

Datum 2024-10-23, kl 10:00
Källa MFN
Bifogade filer
Leading global pharma company evaluates AcouWash for quality control in an R&D setting
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!